Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics
A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of CVX-096 In Type 2 Diabetic Adult Subjects
Status: Enrolling
Updated:  7/30/2015
Pfizer Investigational Site
mi
from
San Antonio, TX
A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics
A Phase 1, Placebo-Controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Escalating Subcutaneous Doses Of CVX-096 In Type 2 Diabetic Adult Subjects
Status: Enrolling
Updated: 7/30/2015
Pfizer Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
A Double-blind Study of the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
Status: Enrolling
Updated:  7/30/2015
Oregon Health and Science University/Legacy Health System
mi
from
Portland, OR
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
A Double-blind Study of the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
Status: Enrolling
Updated: 7/30/2015
Oregon Health and Science University/Legacy Health System
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Little Rock Diagnostic Center (LRDC)
mi
from
Little Rock, AR
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Little Rock Diagnostic Center (LRDC)
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
University of Colorado Anschutz Health and Wellness Center
mi
from
Aurora, CO
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
University of Colorado Anschutz Health and Wellness Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Kentucky Research Group
mi
from
Louisville, KY
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Kentucky Research Group
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Tulane University Health Sciences Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Medstar Health Research Institute
mi
from
Hyattsville, MD
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Medstar Health Research Institute
mi
from
Hyattsville, MD
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Massachusetts General Hospital
mi
from
Boston, MA
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
University of Michigan
mi
from
Ann Arbor, MI
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Mayo Clinic Minnesota
mi
from
Rochester, MN
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Mayo Clinic Minnesota
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Washington University
mi
from
St Louis, MO
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Washington University
mi
from
St Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Billings Clinic
mi
from
Billings, MT
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Billings Clinic
mi
from
Billings, MT
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Beth Israel Med Ctr
mi
from
New York, NY
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Cleveland Clinic
mi
from
Cleveland, OH
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Legacy Research Institute
mi
from
Portland, OR
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Legacy Research Institute
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Endocrinology Consultants of East Tennessee & Gastrointestinal Associates
mi
from
Knoxville, TN
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Endocrinology Consultants of East Tennessee & Gastrointestinal Associates
mi
from
Knoxville, TN
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Dallas Diabetes
mi
from
Dallas, TX
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Dallas Diabetes
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
The Methodist Hospital Research Institute
mi
from
Houston, TX
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
The Methodist Hospital Research Institute
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Emory University
mi
from
Atlanta, GA
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Northwestern University
mi
from
Chicago, IL
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated:  7/31/2015
Boston Med Ctr
mi
from
Boston, MA
Safety and Efficacy of EndoBarrier in Subjects With Type 2 Diabetes Who Are Obese
A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Comparing the EndoBarrier Gastrointestinal Liner System vs. Sham for Glycemic Improvement in Inadequately Controlled Obese Type 2 Diabetic Subjects on Oral Anti-Diabetes Agents
Status: Enrolling
Updated: 7/31/2015
Boston Med Ctr
mi
from
Boston, MA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Birmingham, AL
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Evanston, IL
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Evanston, IL
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Henderson, NV
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Henderson, NV
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Albuquerque, NM
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Reseach Site
mi
from
Rapid City, SD
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Reseach Site
mi
from
Rapid City, SD
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Houston, TX
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Huntsville, AL
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Huntsville, AL
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Beverly Hills, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Buena Park, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Buena Park, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Chino, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Chino, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Chula Vista, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Chula Vista, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Encinitas, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Encinitas, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Greenbrae, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Greenbrae, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
North Hollywood, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
North Hollywood, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Walnut Creek, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
West Hills, CA
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
West Hills, CA
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Boca Raton, FL
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Hialeah, FL
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  7/31/2015
Clinical Research Facility
mi
from
Miami, FL
Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
A Randomized, Long-Term, Open-Label, 3-Arm, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 7/31/2015
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials